Oracle Investment Management’s Pacific Biosciences PACB Stock Holding History

Oracle Investment Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-250,000	Closed	-$938K	–	26
2024 Q1	$938K	Sell	250,000 -1,537,100	-86%	-$9M	0.62%	18
2023 Q4	$17.5M	Sell	1,787,100 -7,305,900	-80%	-$59.7M	10.66%	2
2023 Q3	$75.9M	Buy	9,093,000 +8,577,900	+1,665%	+$98M	23.3%	2
2023 Q2	$6.85M	Buy	+515,100	New	+$6.26M	5.05%	6
2023 Q1	–	Sell	-70,000	Closed	-$21K	–	31
2022 Q4	$21K	Buy	+70,000	New	+$603K	0.02%	23
2021 Q4	–	Sell	-43,700	Closed	-$50K	–	43
2021 Q3	$50K	Buy	+43,700	New	+$1.29M	0.01%	40
2019 Q2	–	Sell	-500,000	Closed	-$13K	–	19
2019 Q1	$13K	Sell	500,000 -1,409,600	-74%	-$10.2M	﹤0.01%	18
2018 Q4	$281K	Buy	1,909,600 +1,859,600	+3,719%	+$11.8M	0.09%	17
2018 Q3	$46K	Buy	+50,000	New	+$215K	0.01%	19

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oracle Investment Management's PACB Position: Q1 2025 in Review

Oracle Investment Management sold out of Pacific Biosciences (PACB) in Q1 2025, closing a stake of 279,638 shares — an estimated $512K sold.

Oracle Investment Management first reported a position in PACB in Q2 2013 and held it in 47 quarters. The position peaked at $50.8M in Q3 2018. 225 funds tracked by Wall St. Rank hold PACB as of Q1 2025.

Oracle Investment Management reported no remaining Pacific Biosciences position as of Q1 2025 after selling out during the quarter.
Oracle Investment Management sold 279,638 Pacific Biosciences shares in Q1 2025, an estimated $512K.
Oracle Investment Management first reported a position in Pacific Biosciences in Q2 2013 and held it in 47 quarters.
Oracle Investment Management's Pacific Biosciences position peaked at $50.8M in Q3 2018.
225 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2025.

Based on Oracle Investment Management's 13F filing for Q1 2025, filed 15 May 2025.